Semaglutide has become the most in-demand service in the med spa industry almost overnight. Patients who once booked Botox and fillers as their primary aesthetic investments are now spending $400-$600 per month on GLP-1 weight loss programs — and they are actively searching for med spas that offer structured, medically supervised semaglutide protocols. For practice owners who build their programs correctly, med spa semaglutide represents a recurring revenue engine that can generate $500,000 to over $1 million annually.
But launching a semaglutide program is not as simple as finding a compounding pharmacy and writing prescriptions. The practices capturing the largest share of this market have invested in proper medical oversight, compliant sourcing, structured patient protocols, strategic pricing, and marketing systems that convert high-intent searchers into long-term program members. The ones doing it haphazardly — cutting corners on compliance, neglecting patient screening, or competing purely on price — face regulatory risk, poor outcomes, and unsustainable churn.
This guide walks you through every component of building a semaglutide weight loss program that is clinically sound, legally compliant, and built to generate sustainable revenue for your med spa.
Market Opportunity: The GLP-1 medication market is projected to exceed $100 billion globally by 2030. Google searches for "semaglutide near me" have increased over 500% since 2023. Med spas with structured semaglutide programs report that weight loss services now account for 25-40% of total practice revenue — and the category is still growing.
1. Why Semaglutide Is the Biggest Opportunity in Aesthetics
Understanding the forces driving semaglutide demand helps you position your program for long-term growth rather than treating it as a passing trend. The clinical results, consumer awareness, and economic model all point to sustained, structural growth in med spa weight loss services.
The Clinical Revolution
Semaglutide (marketed as Wegovy for weight loss and Ozempic for type 2 diabetes) is a GLP-1 receptor agonist that fundamentally changes how the body regulates appetite and satiety. The STEP clinical trial program demonstrated results that no previous weight loss intervention could match:
- Average weight loss of 15-17% of total body weight over 68 weeks — roughly 35 pounds for a 220-pound patient, with some patients losing 50+ pounds
- Cardiovascular benefits: The SELECT trial showed a 20% reduction in major adverse cardiovascular events, positioning semaglutide as a legitimate medical treatment rather than a cosmetic convenience
- High patient satisfaction: 85%+ of patients on semaglutide report significant improvement in quality of life, body image, and physical function — outcomes that drive referrals and retention
- Sustained results: Patients who remain on maintenance doses maintain the majority of their weight loss long-term, creating ongoing demand for continued treatment
Consumer Demand Is Exploding
Celebrity endorsements, media coverage, and word-of-mouth from patients experiencing dramatic results have created unprecedented consumer awareness:
- Search volume: "Semaglutide weight loss," "semaglutide near me," and "GLP-1 weight loss program" are among the fastest-growing health-related search terms, with monthly volumes exceeding 500,000 combined
- Willingness to pay: Over 60% of interested patients are willing to pay out-of-pocket for semaglutide when insurance does not cover it, with the average patient expecting to spend $400-$600/month
- Addressable market: Over 42% of American adults have obesity (BMI 30+) and another 30% are overweight, representing a total addressable market of over 150 million potential patients
- Demographic breadth: Unlike most aesthetic services that skew heavily female and 30-55 years old, semaglutide programs attract a broader demographic — 35-40% of GLP-1 patients at med spas are male, and age ranges span 25 to 70+
Why Med Spas Win This Market
Med spas are better positioned to capture semaglutide patients than primary care offices, endocrinology clinics, or telehealth-only providers:
- Cash-pay infrastructure: Your patients already pay out-of-pocket for elective services, eliminating the insurance barriers that frustrate patients at traditional medical offices
- Aesthetic cross-sells: Weight loss patients naturally need body contouring services as they lose volume — loose skin, stubborn fat pockets, and body shape concerns drive organic demand for services you already offer
- Concierge experience: Personalized attention, longer appointments, and boutique environments differentiate your program from a 5-minute primary care visit followed by a pharmacy pickup
- Retention model: Your membership and program structure keeps patients engaged for months and years, not just a single prescription fill
Revenue Comparison: The average Botox patient visits 3-4 times per year, spending $1,200-$2,000 annually. The average semaglutide program patient spends $4,800-$7,200 annually on medication management alone — plus $2,000-$6,000 in body contouring, IV therapy, and supplements. Semaglutide patients generate 3-5x the lifetime value of traditional aesthetic patients.
2. Legal and Compliance Requirements
Semaglutide is a prescription medication with significant regulatory requirements. Building compliance into your program from day one protects your practice, your license, and your patients. Cutting corners here creates existential risk — state medical boards are increasingly scrutinizing med spa weight loss programs, and the FDA is actively monitoring the compounding market. Review your overall compliance framework before launching.
FDA Regulatory Framework
Understanding the FDA's position on semaglutide prescribing and compounding is essential:
- Approved indications: Semaglutide is FDA-approved as Wegovy (2.4mg weekly) for chronic weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity. Off-label prescribing for patients who do not meet these criteria carries additional risk
- Compounding regulations: Compounded semaglutide is only legally available when the brand-name product is on the FDA drug shortage list. Monitor the shortage list regularly, as its status directly affects the legality of your compounded supply chain
- 503A vs 503B pharmacies: 503A pharmacies compound patient-specific prescriptions under a licensed pharmacist; 503B outsourcing facilities can compound without individual prescriptions but face stricter FDA oversight and inspection requirements
- Semaglutide salt form: The FDA has taken enforcement action against pharmacies compounding semaglutide sodium salt (a different form than the approved semaglutide base). Make sure your pharmacy compounds the correct form with proper documentation
State-Level Prescribing Authority
Prescribing requirements vary significantly by state, and your program structure must comply with your specific jurisdiction:
- Physician-led states: Some states require a physician (MD or DO) to directly prescribe weight loss medications or maintain close supervisory relationships with mid-level prescribers
- Collaborative practice states: NPs and PAs can prescribe under a collaborative practice agreement with your medical director. The agreement must specifically authorize weight loss medication prescribing
- Full practice authority states: Approximately 26 states allow NPs to prescribe independently, simplifying the operational model but still requiring proper clinical protocols
- Telemedicine prescribing: Many states now allow initial telemedicine consultations for weight loss medications, but some require an in-person visit first. Know your state's telehealth prescribing rules before offering virtual consultations
Advertising and Marketing Compliance
Weight loss advertising is among the most regulated categories in healthcare marketing:
- Never use brand names (Ozempic, Wegovy) in your advertising without authorization — reference "semaglutide" or "GLP-1 medications" instead
- Do not guarantee specific weight loss results. Use language like "patients may experience" or "average results in clinical studies show"
- Before-and-after photos must comply with state medical board guidelines and social media platform policies
- Include appropriate disclaimers: "Results vary. Medical evaluation required. Not appropriate for all patients."
- Make sure your patient safety protocols are documented before any marketing claims reference clinical supervision
3. Setting Up Your Semaglutide Program
The operational foundation of your program determines both clinical outcomes and revenue potential. Practices that invest in proper setup generate higher patient satisfaction, better retention, and fewer compliance issues.
Medical Director Agreement
Your medical director is the clinical backbone of your semaglutide program. Structure the relationship to support growth:
- Compensation models: Fixed monthly fee ($3,000-$8,000/month depending on involvement), revenue share (10-20% of weight loss program revenue), or hybrid. Revenue share aligns incentives as the program grows
- Time commitment: Expect 8-15 hours per month initially for protocol development, chart review, and prescribing. This scales with patient volume
- Specialty preference: Physicians with backgrounds in endocrinology, obesity medicine, or internal medicine bring the most clinical credibility. Board certification in obesity medicine (ABOM) is a significant marketing differentiator
- Protocol development: Your medical director should create written protocols covering patient screening criteria, contraindication lists, dosing schedules, titration guidelines, side effect management, and emergency procedures before you see your first patient
Patient Screening and Lab Requirements
Proper screening protects patients and reduces your liability exposure. Every semaglutide patient should receive:
- Medical history review: Screen for personal or family history of medullary thyroid carcinoma, MEN2 syndrome, pancreatitis, gastroparesis, severe GI disease, and gallbladder disease — all contraindications or precautions for GLP-1 therapy
- BMI assessment: Verify the patient meets prescribing criteria (BMI 30+ or BMI 27+ with at least one weight-related comorbidity such as hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea)
- Baseline labs: CBC, CMP (including liver and kidney function), lipid panel, HbA1c, thyroid panel (TSH, free T4), and fasting insulin. Partner with a draw station or offer in-house phlebotomy. Lab cost: $30-$80; charge: $150-$250
- Body composition analysis: Use a bioimpedance device (InBody, Tanita) to establish baseline body fat percentage, lean muscle mass, visceral fat level, and basal metabolic rate. Device cost: $3,000-$8,000; per-scan cost: $0
- Mental health screening: Screen for eating disorders (binge eating disorder is common in this population and actually responds well to GLP-1 therapy; anorexia and bulimia are contraindications)
- Standardized before photos: Multiple angles with consistent lighting. These become powerful marketing assets (with consent) and motivational tools for the patient
Clinical Protocols
Document your semaglutide dosing protocol in writing. The standard titration schedule:
- Weeks 1-4: Semaglutide 0.25mg subcutaneous injection weekly (titration dose)
- Weeks 5-8: 0.5mg weekly
- Weeks 9-12: 1.0mg weekly
- Weeks 13-16: 1.7mg weekly (if tolerated and weight loss is progressing)
- Week 17+: 2.4mg weekly (therapeutic target dose for weight loss)
- Dose adjustments: Slow titration for patients with significant GI side effects. Some patients achieve satisfactory weight loss at 1.0-1.7mg and do not need to reach 2.4mg — a benefit with compounded formulations where you control dosing flexibly
Clinical Tip: The most common reason patients discontinue semaglutide is GI side effects during the first 4-8 weeks — primarily nausea, constipation, and reduced appetite to the point of food aversion. Proactive side effect management (anti-nausea protocols, hydration guidance, fiber supplementation, slower titration when needed) dramatically improves retention through this critical early period.
4. Sourcing and Supply Chain
Your medication sourcing strategy directly impacts margins, patient pricing, compliance risk, and program sustainability. There are three models, and the most successful practices maintain capabilities for at least two of them.
Compounded Semaglutide (503A and 503B Pharmacies)
Compounded semaglutide offers the most favorable economics for GLP-1 med spa programs:
- Cost per patient per month: $40-$100 depending on dose, pharmacy, and volume pricing
- Patient price: $350-$500/month (including medication, monitoring, and program fees)
- Gross margin: 55-70% on the all-inclusive program fee
- 503A pharmacies: Compound patient-specific prescriptions. Require an individual prescription for each patient. Typically lower minimums but potentially higher per-unit cost
- 503B outsourcing facilities: Can compound in bulk without individual prescriptions. Subject to FDA inspections and cGMP standards. Generally offer better volume pricing and more consistent supply
Vetting Your Compounding Pharmacy
Not all compounding pharmacies are equal. Protect your patients and practice by verifying:
- FDA registration: Confirm the pharmacy is registered with the FDA as a 503A or 503B facility
- State licensure: Verify active pharmacy licenses in both the pharmacy's home state and your state (interstate compounding requires licensure in the receiving state)
- Sterility testing: Request certificates of analysis showing sterility testing results for each batch. Injectable semaglutide must meet USP 797 sterility standards
- Potency verification: Confirm the pharmacy tests each batch for semaglutide concentration/potency. The labeled dose must match the actual content within acceptable variance (typically +/- 10%)
- Beyond-use dating: Verify the assigned beyond-use date is supported by stability testing data, not arbitrary estimates
- Insurance: Confirm the pharmacy carries adequate professional liability insurance
Brand-Name Semaglutide (Wegovy)
Offering brand-name Wegovy as an option serves patients who prefer FDA-approved products:
- Patient cost: $1,000-$1,600/month without insurance coverage
- Your revenue model: Charge a monthly program fee ($200-$400) covering consultations, monitoring, body composition tracking, and coaching — separate from the medication cost the patient pays at a retail or specialty pharmacy
- Margin on program fee: 80-90% (you carry no medication cost or liability)
- Advantages: No medication sourcing liability, no compounding regulatory risk, some patients have insurance coverage
- Disadvantage: Higher total cost to patients limits your addressable market and you lose the medication margin
Hybrid Sourcing Strategy
The most resilient approach offers both options, with tiered pricing that matches patient budgets:
- Premium tier: Brand-name Wegovy + concierge program with weekly provider access, nutritional coaching, supplement bundle, and priority body contouring scheduling. Total: $1,400-$2,000/month
- Standard tier: Compounded semaglutide + biweekly monitoring, group nutrition sessions, and body composition tracking. Total: $400-$550/month
- Essential tier: Compounded semaglutide + monthly check-in and telemedicine support. Total: $300-$400/month. Designed for price-sensitive patients and high-volume scaling
Supply Chain Risk: The FDA shortage status of semaglutide can change with limited notice, potentially affecting the legality of compounded supply. Maintain relationships with at least two compounding pharmacies, keep 30-45 days of inventory buffer, and have a documented plan for transitioning patients to brand-name products if compounding access is restricted. Practices that fail to plan for supply disruption face catastrophic patient churn when shortages end.
5. Pricing and Packages
Your pricing strategy determines both patient volume and per-patient profitability. The most successful semaglutide programs use structured packages rather than per-visit billing, which improves retention, simplifies operations, and increases lifetime value.
Monthly Program Pricing
The dominant pricing model for semaglutide weight loss programs is an all-inclusive monthly fee:
- What is included: Compounded semaglutide medication, injection supplies, monthly or biweekly provider visits (in-person or telehealth), body composition scans, nutritional guidance, and secure messaging support
- Market pricing range: $350-$600/month depending on market, service level, and whether medication is included
- Median market price: $450/month for compounded semaglutide programs with monthly provider visits
- Margin at $450/month: Medication cost $60-$80, provider time $30-$50, supplies and overhead $20-$30. Net margin: $290-$340 per patient per month (64-75%)
Bundled Packages with Body Contouring
Bundling semaglutide with body contouring creates strong value propositions and increases average patient spend:
- "Complete Transformation" package: 6 months semaglutide program + 4 CoolSculpting or Emsculpt NEO sessions. Bundle price: $5,500-$7,500 (vs. $6,500-$9,000 purchased separately). Savings perception drives enrollment while locking in high-value commitments
- "Slim and Sculpt" package: 3 months semaglutide + 2 body contouring sessions. Entry-level bundle at $2,800-$3,800 for patients hesitant about longer commitments
- Body contouring timing: Schedule body contouring treatments during months 4-6 of the weight loss journey, when patients have lost significant weight but still have stubborn fat deposits. This timing maximizes both clinical results and patient satisfaction
Membership Tiers
Integrate semaglutide into your membership program to maximize retention and lifetime value:
- Weight Loss Member: $399-$499/month. Includes semaglutide, monthly visits, body composition tracking, 10% off all other services, and priority booking. 6-month minimum commitment
- Wellness Plus Member: $599-$799/month. Adds weekly B12 or lipotropic injections, monthly IV therapy session, supplement bundle, and nutritional coaching. Annual commitment with month 13 free
- VIP Transformation Member: $899-$1,199/month. All-inclusive: semaglutide, unlimited B12/lipo injections, biweekly IV therapy, body contouring credits (1 session/month), dedicated concierge coordinator, and provider direct messaging. Annual commitment
Automate Your Semaglutide Program Management
RunMedSpa handles patient onboarding, medication tracking, dosing schedules, refill reminders, body composition monitoring, and retention communication — so you can scale to 200+ weight loss patients without the operational overhead.
Join the Waitlist6. Marketing Your Semaglutide Program
The practices generating the highest patient volume for their semaglutide programs use multi-channel strategies anchored in education, social proof, and search visibility. Your marketing plan should treat weight loss as a distinct campaign with its own budget, messaging, and conversion funnel.
Search Engine Optimization
Weight loss and semaglutide keywords have enormous search volume with strong commercial intent:
- Primary keywords to target: "[your city] semaglutide," "semaglutide weight loss near me," "GLP-1 weight loss program [city]," "medical weight loss [city]"
- Content strategy: Publish educational articles answering patient questions: "semaglutide side effects," "semaglutide vs tirzepatide," "how much weight can I lose on semaglutide," "semaglutide cost without insurance." Each article builds topical authority and captures long-tail search traffic
- Local SEO: Optimize your Google Business Profile for weight loss keywords. Add semaglutide as a service, post weekly updates about your program, and request reviews specifically mentioning weight loss results
- Service page optimization: Create a dedicated "Semaglutide Weight Loss Program" page with full program details, pricing transparency, provider credentials, FAQs, and clear CTAs
Social Media and Before/After Content
Weight loss transformations are among the most engaging content categories in aesthetics marketing:
- Patient transformation stories: Before-and-after photos with written or video testimonials (with HIPAA-compliant consent) generate massive engagement and referrals. Video testimonials where patients describe their experience are especially powerful
- Educational short-form video: Reels, TikToks, and YouTube Shorts explaining how semaglutide works, debunking myths, and answering common questions position your providers as trusted experts. Topics like "3 things I wish every semaglutide patient knew" and "semaglutide mistakes that slow your results" consistently drive views
- Provider authority content: Your prescribing provider discussing treatment protocols, sharing clinical knowledge, and explaining why your program is different from telehealth prescription mills builds trust and justifies premium pricing
- Patient journey content: With consent, document a patient's journey through your program — consultation, first injection, monthly check-ins, milestones, body contouring. Serial content builds audience investment and demonstrates your program's structure
Google Ads and Paid Acquisition
Paid search and social advertising can accelerate patient acquisition once your program is operational:
- Google Ads: Target "semaglutide [city]," "medical weight loss near me," and "GLP-1 weight loss program [city]." Expect $15-$45 cost per click and $100-$350 cost per lead. With average patient lifetime value of $5,000-$10,000+, even expensive leads are highly profitable
- Meta (Facebook/Instagram) Ads: Use educational content and transformation stories as creative. Focus on consultation offers rather than direct medication advertising to comply with platform policies
- Referral incentives: Offer $100-$200 credit to existing patients who refer new weight loss patients. Referral leads convert at 2-3x the rate of cold advertising leads and have 30-50% higher retention rates
- Lead nurture sequences: Not every lead books immediately. Build an email nurture sequence that educates prospects about your program, shares patient stories, answers objections, and offers consultation scheduling over a 30-60 day period
Marketing Benchmark: Successful med spa semaglutide programs report patient acquisition costs of $150-$400. With average patient retention of 8-14 months and $400-$600 monthly program revenue, the return on marketing investment exceeds 10:1 within each patient's first year. Allocate 15-20% of projected program revenue to marketing during the first 6 months, then reduce to 8-12% as referral volume grows.
7. Patient Experience and Retention
The difference between a $300,000 semaglutide program and a $1 million program is patient retention. Patients who stay in your program for 12+ months generate 3-5x the lifetime value of patients who drop off after the initial prescription. Every element of your patient experience should be designed to reduce churn and increase engagement.
Structured Check-In Cadence
Design your touchpoint schedule to match the patient's clinical needs and emotional journey:
- Week 1: Full assessment, baseline labs, body composition, first injection (in-office to teach self-injection technique), and nutrition plan. 45-60 minutes
- Week 2: Phone or telehealth check-in (10 minutes). Address nausea, appetite changes, injection technique questions, and hydration
- Week 4: In-person visit with body composition scan, dose titration to 0.5mg, and early progress review. 20 minutes
- Week 8: In-person visit with body composition scan, progress photos, dose optimization, and introduction to body contouring options. 25 minutes
- Week 12: Comprehensive review with full body composition, progress photos, lab reassessment, celebration of milestones, and transition to extended program. 30 minutes
- Months 4-12: Monthly in-person visits (20 minutes) with body composition tracking and dose management. Telehealth option for stable patients
Nutritional Counseling and Lifestyle Support
Semaglutide dramatically reduces appetite, but patients still need guidance on what to eat when they do eat — particularly around protein intake, which is critical to preserving lean muscle mass during rapid weight loss:
- Protein targets: GLP-1 patients should consume 80-120g of protein daily (1.0-1.2g per kg of ideal body weight) to minimize muscle loss. Most patients need active coaching to meet these targets with reduced appetite
- Group nutrition sessions: Monthly 45-60 minute group sessions (4-8 patients) deliver coaching efficiently at $50-$75 per session while building community. Topics: meal planning, protein strategies, managing social eating, and dealing with food aversion
- Supplement integration: Protein powder, probiotics (for GI side effects), fiber supplements (for constipation), and multivitamins are clinically appropriate add-ons with 50-60% margins
- Exercise guidance: Resistance training is particularly important for GLP-1 patients to preserve lean mass. Partner with a personal trainer or fitness studio for referrals, or offer on-site guidance
Combination Treatments
Build a treatment ecosystem around your semaglutide program that enhances results and increases revenue per patient:
- B12 and lipotropic injections: $25-$75 per injection, weekly or biweekly. Support energy and fat metabolism during caloric restriction. Offer as an included member perk or affordable add-on
- IV hydration therapy: $150-$300 per session. "Weight Loss Boost" formulas with B-complex, amino acids, and L-carnitine. 85%+ margins, 30-45 minute sessions
- Body contouring: CoolSculpting ($3,000-$6,000 per treatment series), Emsculpt NEO ($3,000-$4,000 for 4 sessions), and RF skin tightening ($1,000-$3,000 per area). 40-60% of weight loss patients purchase body contouring during months 4-8
- Skin treatments: Weight loss can improve skin health but may also reveal sun damage and texture issues previously obscured by excess weight. Chemical peels, microneedling, and laser treatments become relevant as patients' relationship with their appearance evolves
Retention Systems
Practices with the highest semaglutide patient retention (12-18+ month average) implement these systems:
- Progress visualization: Show patients their body composition trends — fat mass decreasing, lean mass preserved, visceral fat dropping. Data-driven progress is more motivating than the scale alone
- Milestone celebrations: Recognize 10%, 15%, and 20% body weight milestones with personalized acknowledgment — a congratulatory message, small gift, or complimentary service. These moments create emotional anchoring to your practice
- Community building: Private patient groups (online or in-person), group coaching sessions, or patient events create accountability and connection that medication alone cannot provide
- Automated touchpoints: SMS and email sequences between visits: medication reminders, hydration and protein tips, motivational messages, and educational content. Automation maintains engagement without consuming provider time
8. Common Pitfalls and How to Avoid Them
Learning from the mistakes of other practices saves you time, money, and potentially your medical license. These are the most common failures in med spa semaglutide programs:
Pitfall 1: Inadequate Medical Oversight
Some med spas treat semaglutide as a "plug and play" product — hiring a medical director in name only, skipping baseline labs, and using cookie-cutter dosing without individualization. This creates clinical risk (adverse events in unscreened patients), regulatory risk (state medical boards auditing your protocols), and retention risk (patients experiencing preventable side effects leave your program and leave negative reviews).
Solution: Invest in a medical director who is genuinely engaged in protocol development and chart review. Budget for proper labs and screening. Document everything.
Pitfall 2: Competing on Price Alone
A race to the bottom on semaglutide pricing ($199/month ads, $149 first-month specials) attracts price-sensitive patients with the lowest retention rates, lowest cross-sell potential, and highest customer service demands. It also compresses margins to the point where the program is barely profitable.
Solution: Compete on program quality, clinical outcomes, and patient experience rather than price. Charge $400-$550/month and deliver a structured, high-touch program that justifies the premium. Patients paying $450/month with excellent support stay 3x longer than patients paying $199/month with minimal contact.
Pitfall 3: Ignoring Supply Chain Risk
Practices that rely on a single compounding pharmacy with no backup plan face catastrophic disruption when supply issues arise — whether from FDA enforcement action, pharmacy quality failures, or shortage status changes.
Solution: Maintain active relationships with at least two compounding pharmacies. Keep 30-45 days of medication inventory. Have a documented transition plan for moving patients to brand-name products if compounding access is restricted.
Pitfall 4: No Retention Infrastructure
Prescribing semaglutide without a structured program is like selling gym memberships without classes or trainers. Patients who receive a prescription and nothing else drop off at 60-70% within the first 4 months. Without check-ins, body composition tracking, nutritional guidance, and milestone recognition, you are leaving $3,000-$5,000 per patient in lifetime value on the table.
Solution: Build a multi-phase program (12-week foundation, 6-month extended, ongoing maintenance) with structured touchpoints at every stage. Invest in automated communication systems that keep patients engaged between visits.
Pitfall 5: Failing to Cross-Sell
Many med spas treat weight loss as a standalone service, missing the organic cross-sell opportunities that multiply patient lifetime value by 2-3x. Weight loss patients need body contouring, IV therapy, supplements, and eventually maintenance aesthetic services — but only if you proactively introduce these services at the right moment in their journey.
Solution: Map cross-sell conversations to specific points in the patient journey. Month 2: introduce IV therapy and supplements. Month 4: body contouring consultation. Month 8: skin treatments for post-weight-loss skin concerns. Month 12+: aesthetic maintenance program.
Frequently Asked Questions
How much does it cost to start a semaglutide program at a med spa?
Launching a semaglutide program typically requires $15,000-$40,000 in startup investment, covering medical director agreement, initial medication inventory, body composition equipment, EMR setup, staff training, and initial marketing. Most practices recoup their startup investment within 60-90 days, as each active patient generates $400-$600/month in recurring revenue with 55-70% gross margins on compounded semaglutide programs.
Can a med spa legally prescribe semaglutide for weight loss?
Yes, med spas can legally offer semaglutide under proper medical oversight. A licensed prescriber (MD, DO, NP, or PA depending on state laws) must conduct a medical evaluation, confirm the patient meets prescribing criteria, and provide ongoing clinical supervision. Most med spas operate under a medical director who establishes treatment protocols and oversees all prescribing activity.
Should I use compounded or brand-name semaglutide?
Most med spas use compounded semaglutide for better economics ($40-$100/month per patient vs. $1,000-$1,600 for brand-name Wegovy), enabling competitive pricing at $350-$500/month with strong margins. However, compounding is only legal when brand-name products are on the FDA shortage list. Maintain relationships with both compounding pharmacies and brand-name distributors to make sure continuity regardless of regulatory changes.
How many patients do I need for a profitable semaglutide program?
A semaglutide program becomes meaningfully profitable at 30-50 active patients and reaches maturity at 100-200. At 30 patients averaging $450/month, you generate $162,000 annually. At 100 patients, annual revenue reaches $540,000. At 150-200 patients with body contouring cross-sells, total program revenue can exceed $1.5 million. One full-time NP or PA can manage 80-120 active patients.
Build Your Semaglutide Program for Long-Term Growth
Semaglutide is not a fad — it represents a fundamental shift in how weight management is delivered. The clinical evidence is strong, patient demand is accelerating, and the recurring revenue model creates financial stability that transactional aesthetic services cannot match. Med spas that build structured, compliant, patient-centered semaglutide programs today are establishing competitive advantages that will compound for years.
The practices winning in this space share common traits: they invest in proper medical oversight rather than cutting corners, they build multi-phase programs rather than writing prescriptions, they compete on patient experience rather than price, and they treat semaglutide as the anchor of a broader weight loss service ecosystem rather than a standalone product. The startup investment is modest ($15,000-$40,000), the payback period is fast (60-90 days), and the revenue ceiling is high ($1 million+ annually for mature programs).
Whether you are launching your first semaglutide program or optimizing an existing one, the principles in this guide provide the operational, clinical, and strategic framework for building a weight loss service that serves your patients and transforms your practice economics.
Ready to Launch Your Semaglutide Program?
RunMedSpa automates patient onboarding, medication tracking, dosing protocols, body composition monitoring, and retention communication — everything you need to scale a profitable semaglutide program without operational complexity.
Join the Waitlist Today